Genetic Technologies

Genetic Technologies Limited is a molecular diagnostics company focused on women's health, primarily operating in Australia and the United States. The company's flagship product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer, marketed to healthcare professionals including breast surgeons and obstetricians/gynecologists. In addition to BREVAGenplus, Genetic Technologies is developing a range of cancer risk assessment tests under the GeneType brand for colorectal and breast cancer. The company also provides various genetic testing services, encompassing medical, animal, forensic, and plant testing. Genetic Technologies has established research and collaboration agreements with several prestigious institutions, including the University of Melbourne and Memorial Sloan Kettering Cancer Center, enhancing its innovation and research capabilities. Founded in 1989 and headquartered in Fitzroy, Australia, Genetic Technologies aims to maintain a dominant position in the genetic testing market by delivering tests that significantly impact clinical outcomes.